Euroopa Liit - slovaki - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - hydrokortizon - adrenálna nedostatočnosť - kortikosteroidy na systémové použitie - liečba adrenálnej insuficiencie u dospelých.

Slovakkia - slovaki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

adamed pharma s.a., poľsko - eplerenón - 50 - diuretica

Slovakkia - slovaki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

adamed pharma s.a., poľsko - eplerenón - 50 - diuretica

Slovakkia - slovaki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

les laboratoires servier - perindopril,amlodipín a indapamid - 58 - hypotensiva

Slovakkia - slovaki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

les laboratoires servier - perindopril,amlodipín a indapamid - 58 - hypotensiva

Slovakkia - slovaki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

les laboratoires servier - perindopril,amlodipín a indapamid - 58 - hypotensiva

Slovakkia - slovaki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

les laboratoires servier - perindopril,amlodipín a indapamid - 58 - hypotensiva

Euroopa Liit - slovaki - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastické činidlá - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Euroopa Liit - slovaki - EMA (European Medicines Agency)

almirall s.a - dimetylfumarát - svrab - imunosupresíva - skilarence je indikovaný na liečbu stredne závažnej až závažnej ložiskovej psoriázy u dospelých potrebuje systémové liečivý terapia.

Euroopa Liit - slovaki - EMA (European Medicines Agency)

lipomed gmbh - talidomid - viacnásobný myelóm - imunosupresíva - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.